Applications of the Cholesterol Metabolite, 4β-Hydroxycholesterol, as a Sensitive Endogenous Biomarker for Hepatic CYP3A Activity Evaluated within a PBPK Framework
Open Access
- 30 September 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (10) , 1284
Abstract
Background/Objectives: Plasma levels of 4β-hydroxycholesterol (4β-OHC), a CYP3A-specific metabolite of cholesterol, are elevated after administration of CYP3A inducers like rifampicin and carbamazepine. To simulate such plasma 4β-OHC increase, we developed a physiologically based pharmacokinetic (PBPK) model of cholesterol and 4β-OHC in the Simcyp PBPK Simulator (Version 23, Certara UK Ltd.) using a middle-out approach. Methods: Relevant physicochemical properties and metabolic pathway data for CYP3A and CYP27A1 was incorporated in the model. Results: The PBPK model recovered the observed baseline plasma 4β-OHC levels in Caucasian, Japanese, and Korean populations. The model also captured the higher baseline 4β-OHC levels in females compared to males, indicative of sex-specific differences in CYP3A abundance. More importantly, the model recapitulated the increased 4β-OHC plasma levels after multiple-dose rifampicin treatment in six independent studies, indicative of hepatic CYP3A induction. The verified model also captured the altered 4β-OHC levels in CYP3A4/5 polymorphic populations and with other CYP3A inducers. The model is limited by scant data on relative contributions of CYP3A and CYP27A1 pathways and does not account for regulatory mechanisms that control plasma cholesterol and 4β-OHC levels. Conclusion: This study provides a quantitative fit-for-purpose and framed-for-future modelling framework for an endogenous biomarker to evaluate the DDI risk with hepatic CYP3A induction.Keywords
This publication has 73 references indexed in Scilit:
- PBPK perspective on alternative CYP3A4 inducers for rifampinCPT: Pharmacometrics & Systems Pharmacology, 2022
- Physiological‐based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20‐years; in‐depth analysis of applications, organizations, and platformsBiopharmaceutics & Drug Disposition, 2020
- The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to MidazolamClinical Pharmacology & Therapeutics, 2020
- Use of 4β‐Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 DiabetesClinical Pharmacology & Therapeutics, 2019
- Development of a Korean‐specific virtual population for physiologically based pharmacokinetic modelling and simulationBiopharmaceutics & Drug Disposition, 2019
- PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3CPT: Pharmacometrics & Systems Pharmacology, 2018
- Tacrolimus Elimination in Four Patients With a CYP3A5*3/*3 CYP3A4*22/*22 Genotype CombinationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
- Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium PerspectiveClinical Pharmacology & Therapeutics, 2018
- Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy SubjectsThe Journal of Clinical Pharmacology, 2016
- Regulation of Cholesterol And Bile Acid Homeostasis by the Cholesterol 7α-Hydroxylase/Steroid Response Element-Binding Protein 2/Microrna-33A Axis in MiceHepatology, 2013